HDR Brachytherapy as Monotherapy for Prostate Cancer: Early Toxicity of a Randomized Phase II Trial

被引：0
|
作者：
Jolicoeur, M. [1 ]
Derashodian, T. [1 ]
Nguyen-Huynh, T. [1 ]
Hillmann, E. de Castro [1 ]
Berbiche, D. [2 ]
Truchon, D. [1 ]
Heliou, R. [1 ]
Mondat, M. [1 ]
机构：
[1] Charles LeMoyne Hosp, Radiol Oncol, Greenfield Pk, PQ, Canada
[2] Charles LeMoyne Hosp, Ctr Rech, Greenfield Pk, PQ, Canada
来源：
RADIOTHERAPY AND ONCOLOGY | 2021年 / 158卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP-0121
引用
收藏
页码：S90 / S91
页数：2
相关论文
共 50 条
  • [1] HDR brachytherapy Monotherapy for prostate cancer: a one-day schedule phase II trial acute toxicity
    Jolicoeur, M.
    Nguyen, T. V.
    Derashodian, T.
    Hill, E.
    Mondat, M.
    Nachabe, M.
    Antebi, E.
    Wakil, G.
    Heliou, R.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S139 - S140
  • [2] HDR BRACHYTHERAPY AS MONOTHERAPY FOR EARLY STAGE PROSTATE CANCER: ACUTE TOXICITY
    Aluwini, S.
    van Rooij, P.
    Kirkels, W.
    Bangma, C.
    Kolkman-Deurloo, I. K.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2011, 99 : S283 - S284
  • [3] QoL and toxicity of HDR prostate brachytherapy as monotherapy 19Gy single fraction: phase II trial
    Gomez-Iturriaga, A.
    Casquer, F.
    Minguez, P.
    Espinosa, J.
    Bueso, A.
    Cacicedo, J.
    Fernandez, L.
    Pedraza, S.
    Garcia Escovedo, J.
    Bilbao, P.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S139 - S140
  • [4] Conformal HDR brachytherapy as monotherapy in early stage prostate cancer
    Martin, T
    Baltas, D
    Kurek, R
    Röddiger, S
    Tunn, UW
    Zamboglou, N
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2004, 180 : 1 - 1
  • [5] HDR brachytherapy as a single-day monotherapy: Survival results of a phase II randomized trial
    Jolicoeur, M.
    Derashodian, T.
    Nguyen-Huynh, T.
    Hillmann, E.
    Denis, T.
    Heliou, R.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2021, 158 : S70 - S70
  • [6] Early toxicity in a randomized trial of high dose-rate (HDR) brachytherapy as monotherapy for low- and intermediate-risk prostate cancer.
    Morton, Gerard
    Chung, Hans T.
    McGuffin, Merrylee
    Zhang, Liying
    Ravi, Ananth
    D'Alimonte, Laura
    Loblaw, Andrew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [7] Toxicity and Quality of Life Outcomes from a Randomized Phase II Trial of HDR Monotherapy for Low and Intermediate-Risk Prostate Cancer
    Hasan, Y.
    Loblaw, D. A.
    Chung, H. R.
    McGuffin, M.
    Tseng, C. L.
    Mendez, L. C.
    Ravi, A.
    Zhang, L.
    Mamedov, A.
    Morton, G.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S133 - S133
  • [8] TOXICITY AND QUALITY OF LIFE RESULTS FROM A RANDOMIZED PHASE II TRIAL OF HDR MONOTHERAPY FOR LOW AND INTERMEDIATE-RISK PROSTATE CANCER
    Hasan, Yaser
    Loblaw, Andrew
    Chung, Hans
    McGuffin, Merrylee
    Tseng, Chia-Lin
    Mendez, Lucas
    Ravi, Ananth
    Zhang, Liying
    Mamedov, Alexandre
    Morton, Gerard
    [J]. RADIOTHERAPY AND ONCOLOGY, 2019, 139 : S36 - S36
  • [9] HDR monotherapy brachytherapy for localised prostate cancer
    Hoskin, P. J.
    Bownes, P.
    Bryant, L.
    Ostler, P.
    [J]. CLINICAL ONCOLOGY, 2007, 19 (03) : S7 - S7
  • [10] High-Dose-RATE Brachytherapy As Monotherapy for Low and Intermediate Risk Prostate Cancer: ACUTE Toxicity of a Randomized Phase II Trial
    Jolicoeur, M.
    Derashodian, T.
    Nguyen-Huynh, T. V.
    Hellmann, E. de Castro
    Mondat, M.
    Nachabe, M.
    Antebi, E.
    Wakil, G.
    Heliou, R.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E284 - E284
12345